What is Lamictal used for?

Indications and Usage, quoted from the label by GlaxoSmithKline LLC (NDA022115). Cross-references to other label sections are left out.

Adjunctive Therapy

LAMICTAL XR is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.

Monotherapy

LAMICTAL XR is indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED).

Safety and effectiveness of LAMICTAL XR have not been established as initial monotherapy or for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

Limitation of Use

Safety and effectiveness of LAMICTAL XR for use in patients younger than 13 years have not been established.

Source: DailyMed label, set id 3e2c9a35-6a39-41d7-ad84-3c0bb8894b09, version 44, effective October 10, 2025. NDC 0173-0754, one of 6 listings for this product.

Indications and Usage, quoted from the label by GlaxoSmithKline LLC (NDA020241). Cross-references to other label sections are left out.

Epilepsy

Adjunctive Therapy

LAMICTAL is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older:

• partial-onset seizures.
• primary generalized tonic-clonic (PGTC) seizures.
• generalized seizures of Lennox-Gastaut syndrome.

Monotherapy

LAMICTAL is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).

Safety and effectiveness of LAMICTAL have not been established as initial monotherapy; for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

Bipolar Disorder

LAMICTAL is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy.

Limitations of Use

Treatment of acute manic or mixed episodes is not recommended. Effectiveness of LAMICTAL in the acute treatment of mood episodes has not been established.

Source: DailyMed label, set id d7e3572d-56fe-4727-2bb4-013ccca22678, version 45, effective October 10, 2025. NDC 0173-0633, one of 4 listings for this product.